Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

2.16
USD
-0.14
(-6.09%)
-0.15EPS
374.62MMarket Cap
Mar 01Next Earn
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
(Nasdaq Stock Market)

Recent

price

2.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-3.89
-4.86
-4.04
-14.88
-6.41
-4.36
-1.89
-1.58
-2.52
-2.67
-3.26
-2.92
-2.73
-2.01
-0.15
Basic EPS, GAAP
-3.3
-3.07
-2.85
-3.89
-5.65
-3.87
-1.4
-1.79
-1.87
-2.04
-2.74
-2.52
-2.27
-1.71
-1.52
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-17.42
-23.46
-15.09
16.47
10.85
7.02
4.29
5.61
8.25
7.05
6.19
5.46
4.35
2.56
3.37
Book Value per Share
-17.42
-23.46
-15.09
16.47
10.85
7.02
3.61
5.05
7.75
6.57
5.37
4.74
3.75
1.97
2.78
Tangible Book Value per Share
2
2
3
5
7
7
39
49
55
63
68
84
95
111
112
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
6
5
6
7
9
11
10
Depreciation Expense
-6
-8
-10
-68
-43
-29
-75
-77
-140
-169
-222
-246
-259
-223
-17
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2
10
-4
108
121
97
194
289
455
370
325
330
337
163
258
Working Capital
- -
5
3
- -
49
50
41
46
55
20
20
22
23
22
22
LT Debt
-31
-39
-52
109
73
48
194
307
504
455
490
493
463
277
369
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-47.1
-48.78
-61.64
-30.83
-34.46
-35.29
-46.98
-50.01
-54.14
-60.27
-4.77
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
22
22
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
108
109
110
Market Capitalization
380
391
375

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
193
150
290
Cash, Cash Equivalents & STI
189
144
284
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
24
31
Payables & Accruals
15
16
21
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.35%
-9.51%
-40.16%
Free Cash Flow
34.19%
14.54%
-11.66%
Net Income, GAAP
22.35%
10.91%
-13.77%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.66
-0.74
-0.71
-0.62
-2.73
2025
-0.56
-0.62
-0.45
-0.38
-2.01
2026
-0.42
1.09
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Rocket Pharmaceuticals, Inc. (RCKT) is a fully integrated, late-stage biotechnology company that develops gene therapies for rare and devastating pediatric diseases, employing lentiviral vector (LVV) and adeno-associated viral (AAV) platforms to target genetic disorders in hematopoietic stem cells, heart, liver, and other tissues. The company's pipeline includes late-stage LVV programs for KRESLADI (RP-L201) in severe leukocyte adhesion deficiency-I (LAD-I), Fanconi anemia (FA), and pyruvate kinase deficiency (PKD); and AAV programs for Danon disease (RP-A501), plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM, RP-A601), and BAG3 dilated cardiomyopathy (BAG3-DCM). It operates primarily in the United States, with research, development, and manufacturing facilities in Cranbury, New Jersey, where it was founded in 2015. In July 2025, Rocket announced a strategic corporate reorganization to prioritize its AAV cardiovascular platform, including Danon disease, PKP2-ACM, and BAG3-DCM, alongside regulatory efforts for KRESLADI following FDA acceptance of its BLA resubmission in October 2025; this refocuses resources on late-stage assets after a strategy outlined in January 2025. The company targets patient populations with high unmet needs in inherited cardiomyopathies and hematologic disorders, affecting over 100,000 patients in the U.S. and EU, and maintains partnerships with institutions like the University of California and Temple University to advance its therapies.

Company News

  • Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

  • Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference

  • Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

  • Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

  • Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan Capital

  • Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

  • Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

  • Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

  • Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

  • RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

  • Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More

  • Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

  • Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

  • Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

  • Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

  • Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Hold” by Analysts

  • Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

  • Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress